Vertical Research started coverage on shares of Tilray (NASDAQ:TLRY) in a report issued on Friday morning, Benzinga’s Daily Ratings Newsletter reports. The firm issued a sell rating on the stock.
A number of other research analysts have also issued reports on the stock. Piper Jaffray Companies initiated coverage on shares of Tilray in a research note on Wednesday, January 9th. They set an overweight rating and a $90.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Tilray in a research note on Friday, March 8th. They set an underperform rating and a $61.00 price target on the stock. Roth Capital upgraded shares of Tilray from a neutral rating to a buy rating in a research note on Wednesday, February 20th. Seaport Global Securities initiated coverage on shares of Tilray in a research note on Thursday, February 21st. They set a neutral rating and a $81.10 price target on the stock. Finally, Zacks Investment Research upgraded shares of Tilray from a sell rating to a hold rating in a research note on Wednesday, December 26th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $106.52.
Shares of Tilray stock opened at $52.91 on Friday. Tilray has a 52-week low of $20.10 and a 52-week high of $300.00. The company has a current ratio of 21.37, a quick ratio of 20.75 and a debt-to-equity ratio of 2.17. The stock has a market cap of $4.99 billion and a PE ratio of -64.52.
In other Tilray news, CFO Mark Castaneda sold 30,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $70.43, for a total transaction of $2,112,900.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Edward Wood Pastorius, Jr. sold 3,443 shares of the company’s stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $61.04, for a total transaction of $210,160.72. The disclosure for this sale can be found here. Insiders have sold 386,025 shares of company stock worth $26,792,913 over the last 90 days.
Institutional investors and hedge funds have recently modified their holdings of the business. Exane Derivatives grew its position in Tilray by 1,833.0% during the fourth quarter. Exane Derivatives now owns 9,665 shares of the company’s stock worth $683,000 after buying an additional 9,165 shares during the period. First Mercantile Trust Co. grew its position in Tilray by 35.4% during the fourth quarter. First Mercantile Trust Co. now owns 6,500 shares of the company’s stock worth $459,000 after buying an additional 1,700 shares during the period. LPL Financial LLC acquired a new position in Tilray during the third quarter worth about $706,000. IFP Advisors Inc grew its position in Tilray by 61.0% during the fourth quarter. IFP Advisors Inc now owns 1,729 shares of the company’s stock worth $130,000 after buying an additional 655 shares during the period. Finally, Morgan Stanley acquired a new position in Tilray during the third quarter worth about $27,240,000. Institutional investors own 7.91% of the company’s stock.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Recommended Story: Quick Ratio
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.